乳がん(Breast Cancer):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Breast Cancer - Pipeline Review, H2 2014
◆商品コード:GMDHC5546IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:1702
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥780,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における乳がん(Breast Cancer)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・乳がん(Breast Cancer)の概要
・乳がん(Breast Cancer)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・乳がん(Breast Cancer)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・乳がん(Breast Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・乳がん(Breast Cancer)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Breast Cancer – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Breast Cancer – Pipeline Review, H2 2014’, provides an overview of the Breast Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Breast Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Breast Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 14
Breast Cancer Overview 15
Therapeutics Development 16
Breast Cancer – Therapeutics under Development by Companies 18
Breast Cancer – Therapeutics under Investigation by Universities/Institutes 44
Breast Cancer – Pipeline Products Glance 51
Breast Cancer – Products under Development by Companies 55
Breast Cancer – Products under Investigation by Universities/Institutes 89
Breast Cancer – Companies Involved in Therapeutics Development 98
Breast Cancer – Therapeutics Assessment 394
Drug Profiles 429
Breast Cancer – Recent Pipeline Updates 1305
Breast Cancer – Dormant Projects 1589
Breast Cancer – Discontinued Products 1617
Breast Cancer – Product Development Milestones 1623
Appendix 1633

[List of Tables]
Number of Products under Development for Breast Cancer, H2 2014 84
Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2014 85
Number of Products under Development by Companies, H2 2014 87
Number of Products under Development by Companies, H2 2014 (Contd..1) 88
Number of Products under Development by Companies, H2 2014 (Contd..2) 89
Number of Products under Development by Companies, H2 2014 (Contd..3) 90
Number of Products under Development by Companies, H2 2014 (Contd..4) 91
Number of Products under Development by Companies, H2 2014 (Contd..5) 92
Number of Products under Development by Companies, H2 2014 (Contd..6) 93
Number of Products under Development by Companies, H2 2014 (Contd..7) 94
Number of Products under Development by Companies, H2 2014 (Contd..8) 95
Number of Products under Development by Companies, H2 2014 (Contd..9) 96
Number of Products under Development by Companies, H2 2014 (Contd..10) 97
Number of Products under Development by Companies, H2 2014 (Contd..11) 98
Number of Products under Development by Companies, H2 2014 (Contd..12) 99
Number of Products under Development by Companies, H2 2014 (Contd..13) 100
Number of Products under Development by Companies, H2 2014 (Contd..14) 101
Number of Products under Development by Companies, H2 2014 (Contd..15) 102
Number of Products under Development by Companies, H2 2014 (Contd..16) 103
Number of Products under Development by Companies, H2 2014 (Contd..17) 104
Number of Products under Development by Companies, H2 2014 (Contd..18) 105
Number of Products under Development by Companies, H2 2014 (Contd..19) 106
Number of Products under Development by Companies, H2 2014 (Contd..20) 107
Number of Products under Development by Companies, H2 2014 (Contd..21) 108
Number of Products under Development by Companies, H2 2014 (Contd..22) 109
Number of Products under Development by Companies, H2 2014 (Contd..23) 110
Number of Products under Development by Companies, H2 2014 (Contd..24) 111
Number of Products under Investigation by Universities/Institutes, H2 2014 113
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 114
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 115
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 116
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..4) 117
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..5) 118
Comparative Analysis by Late Stage Development, H2 2014 119
Comparative Analysis by Clinical Stage Development, H2 2014 120
Comparative Analysis by Early Stage Development, H2 2014 121
Comparative Analysis by Unknown Stage Development, H2 2014 122
Products under Development by Companies, H2 2014 123
Products under Development by Companies, H2 2014 (Contd..1) 124
Products under Development by Companies, H2 2014 (Contd..2) 125
Products under Development by Companies, H2 2014 (Contd..3) 126
Products under Development by Companies, H2 2014 (Contd..4) 127
Products under Development by Companies, H2 2014 (Contd..5) 128
Products under Development by Companies, H2 2014 (Contd..6) 129
Products under Development by Companies, H2 2014 (Contd..7) 130
Products under Development by Companies, H2 2014 (Contd..8) 131
Products under Development by Companies, H2 2014 (Contd..9) 132
Products under Development by Companies, H2 2014 (Contd..10) 133
Products under Development by Companies, H2 2014 (Contd..11) 134
Products under Development by Companies, H2 2014 (Contd..12) 135
Products under Development by Companies, H2 2014 (Contd..13) 136
Products under Development by Companies, H2 2014 (Contd..14) 137
Products under Development by Companies, H2 2014 (Contd..15) 138
Products under Development by Companies, H2 2014 (Contd..16) 139
Products under Development by Companies, H2 2014 (Contd..17) 140
Products under Development by Companies, H2 2014 (Contd..18) 141
Products under Development by Companies, H2 2014 (Contd..19) 142
Products under Development by Companies, H2 2014 (Contd..20) 143
Products under Development by Companies, H2 2014 (Contd..21) 144
Products under Development by Companies, H2 2014 (Contd..22) 145
Products under Development by Companies, H2 2014 (Contd..23) 146
Products under Development by Companies, H2 2014 (Contd..24) 147
Products under Development by Companies, H2 2014 (Contd..25) 148
Products under Development by Companies, H2 2014 (Contd..26) 149
Products under Development by Companies, H2 2014 (Contd..27) 150
Products under Development by Companies, H2 2014 (Contd..28) 151
Products under Development by Companies, H2 2014 (Contd..29) 152
Products under Development by Companies, H2 2014 (Contd..30) 153
Products under Development by Companies, H2 2014 (Contd..31) 154
Products under Development by Companies, H2 2014 (Contd..32) 155
Products under Development by Companies, H2 2014 (Contd..33) 156
Products under Investigation by Universities/Institutes, H2 2014 157
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 158
Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 159
Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 160
Products under Investigation by Universities/Institutes, H2 2014 (Contd..4) 161
Products under Investigation by Universities/Institutes, H2 2014 (Contd..5) 162
Products under Investigation by Universities/Institutes, H2 2014 (Contd..6) 163
Products under Investigation by Universities/Institutes, H2 2014 (Contd..7) 164
Products under Investigation by Universities/Institutes, H2 2014 (Contd..8) 165
Breast Cancer - Pipeline by 3-V Biosciences, Inc., H2 2014 166
Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H2 2014 167
Breast Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 168
Breast Cancer - Pipeline by AB Science, H2 2014 169
Breast Cancer - Pipeline by AbbVie Inc., H2 2014 170
Breast Cancer - Pipeline by AbGenomics International, Inc., H2 2014 171
Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 172
Breast Cancer - Pipeline by Adaptimmune Limited, H2 2014 173
Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2014 174
Breast Cancer - Pipeline by Advaxis, Inc., H2 2014 175
Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2014 176
Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H2 2014 177
Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H2 2014 178
Breast Cancer - Pipeline by Aeterna Zentaris Inc., H2 2014 179
Breast Cancer - Pipeline by Affichem, H2 2014 180
Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H2 2014 181
Breast Cancer - Pipeline by Alchemia Limited, H2 2014 182
Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2014 183
Breast Cancer - Pipeline by Almac Discovery Ltd., H2 2014 184
Breast Cancer - Pipeline by AlphaMab Co., Ltd, H2 2014 185
Breast Cancer - Pipeline by Alteogen Inc., H2 2014 186
Breast Cancer - Pipeline by Ambrx, Inc., H2 2014 187
Breast Cancer - Pipeline by Amgen Inc., H2 2014 188
Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H2 2014 189
Breast Cancer - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2014 190
Breast Cancer - Pipeline by Angion Biomedica Corp., H2 2014 191
Breast Cancer - Pipeline by AntiCancer, Inc., H2 2014 192
Breast Cancer - Pipeline by Antigen Express, Inc., H2 2014 193
Breast Cancer - Pipeline by Antoxis Limited, H2 2014 194
Breast Cancer - Pipeline by Aphios Corporation, H2 2014 195
Breast Cancer - Pipeline by Aptose Biosciences Inc., H2 2014 196
Breast Cancer - Pipeline by Armour Therapeutics Inc., H2 2014 197
Breast Cancer - Pipeline by Arno Therapeutics, Inc., H2 2014 198
Breast Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 199
Breast Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2014 200
Breast Cancer - Pipeline by Ascentage Pharma Group Corporation, Ltd., H2 2014 201
Breast Cancer - Pipeline by AstraZeneca PLC, H2 2014 202
Breast Cancer - Pipeline by Aurigene Discovery Technologies Limited, H2 2014 203
Breast Cancer - Pipeline by Avipep Pty Ltd, H2 2014 204
Breast Cancer - Pipeline by Axelar AB, H2 2014 205
Breast Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 206
Breast Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2014 207
Breast Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 208
Breast Cancer - Pipeline by Bayer AG, H2 2014 209
Breast Cancer - Pipeline by BBB Therapeutics B.V., H2 2014 210
Breast Cancer - Pipeline by BerGenBio AS, H2 2014 211
Breast Cancer - Pipeline by BHR Pharma, LLC, H2 2014 212
Breast Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2014 213
Breast Cancer - Pipeline by Bionomics Limited, H2 2014 214
Breast Cancer - Pipeline by BioNTech AG, H2 2014 215
Breast Cancer - Pipeline by Bioo Therapeutics, H2 2014 216
Breast Cancer - Pipeline by BiOrion Technologies B.V., H2 2014 217
Breast Cancer - Pipeline by Biotecnol, Inc., H2 2014 218
Breast Cancer - Pipeline by Biotest AG, H2 2014 219
Breast Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2014 220
Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 221
Breast Cancer - Pipeline by Boston Biomedical, Inc., H2 2014 222
Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 223
Breast Cancer - Pipeline by Calithera Biosciences, Inc., H2 2014 224
Breast Cancer - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2014 225
Breast Cancer - Pipeline by Cavion LLC, H2 2014 226
Breast Cancer - Pipeline by CEL-SCI Corporation, H2 2014 227
Breast Cancer - Pipeline by Celgene Corporation, H2 2014 228
Breast Cancer - Pipeline by Cellceutix Corporation, H2 2014 229
Breast Cancer - Pipeline by Celltrion, Inc., H2 2014 230
Breast Cancer - Pipeline by Celsion Corporation, H2 2014 231
Breast Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 232
Breast Cancer - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H2 2014 233
Breast Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2014 234
Breast Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 235
Breast Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 236
Breast Cancer - Pipeline by CIMAB S.A., H2 2014 237
Breast Cancer - Pipeline by Clovis Oncology, Inc., H2 2014 238
Breast Cancer - Pipeline by Cold Genesys, Inc., H2 2014 239
Breast Cancer - Pipeline by Compugen Ltd., H2 2014 240
Breast Cancer - Pipeline by Coronado Biosciences, Inc., H2 2014 241
Breast Cancer - Pipeline by Covagen AG, H2 2014 242
Breast Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2014 243
Breast Cancer - Pipeline by Curadev Pharma Private Limited, H2 2014 244
Breast Cancer - Pipeline by Curaxys, S.L., H2 2014 245
Breast Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H2 2014 246
Breast Cancer - Pipeline by Curis, Inc., H2 2014 247
Breast Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 248
Breast Cancer - Pipeline by CytomX Therapeutics, Inc., H2 2014 249
Breast Cancer - Pipeline by CZ BioMed Corp, H2 2014 250
Breast Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 251
Breast Cancer - Pipeline by Debiopharm International S.A., H2 2014 252
Breast Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 253
Breast Cancer - Pipeline by Dendreon Corporation, H2 2014 254
Breast Cancer - Pipeline by DexTech Medical AB, H2 2014 255
Breast Cancer - Pipeline by Digna Biotech, S.L., H2 2014 256
Breast Cancer - Pipeline by DiNonA Inc., H2 2014 257
Breast Cancer - Pipeline by Dong-A Socio Group, H2 2014 258
Breast Cancer - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2014 259

[List of Figures]
Number of Products under Development for Breast Cancer, H2 2014 84
Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2014 85
Number of Products under Development by Companies, H2 2014 86
Number of Products under Investigation by Universities/Institutes, H2 2014 112
Comparative Analysis by Late Stage Development, H2 2014 119
Comparative Analysis by Clinical Stage Development, H2 2014 120
Comparative Analysis by Early Stage Products, H2 2014 121
Assessment by Monotherapy Products, H2 2014 462
Assessment by Combination Products, H2 2014 463
Number of Products by Top 10 Targets, H2 2014 464
Number of Products by Stage and Top 10 Targets, H2 2014 464
Number of Products by Top 10 Mechanism of Actions, H2 2014 481
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 481
Number of Products by Top 10 Routes of Administration, H2 2014 493
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 493
Number of Products by Top 10 Molecule Types, H2 2014 495
Number of Products by Stage and Top 10 Molecule Types, H2 2014 495

【掲載企業】

3-V Biosciences, Inc.
A&G Pharmaceutical, Inc.
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science
AbbVie Inc.
AbGenomics International, Inc.
Actinium Pharmaceuticals, Inc.
Adaptimmune Limited
Advanced Cancer Therapeutics
Advaxis, Inc.
Advenchen Laboratories, LLC
Aegis Therapeutics, LLC
Aerpio Therapeutics, Inc.
Aeterna Zentaris Inc.
Affichem
Aileron Therapeutics, Inc.
Alchemia Limited
Alethia Biotherapeutics Inc.
Almac Discovery Ltd.
AlphaMab Co., Ltd
Alteogen Inc.
Ambrx, Inc.
Amgen Inc.
Ampio Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc.
Angion Biomedica Corp.
AntiCancer, Inc.
Antigen Express, Inc.
Antoxis Limited
Aphios Corporation
Aptose Biosciences Inc.
Armour Therapeutics Inc.
Arno Therapeutics, Inc.
Arrien Pharmaceuticals, LLC
Ascenta Therapeutics, Inc.
Ascentage Pharma Group Corporation, Ltd.
AstraZeneca PLC
Aurigene Discovery Technologies Limited
Avipep Pty Ltd
Axelar AB
Azaya Therapeutics Incorporated
Basilea Pharmaceutica AG
Bavarian Nordic A/S
Bayer AG
BBB Therapeutics B.V.
BerGenBio AS
BHR Pharma, LLC
Bio-Path Holdings, Inc.
Bionomics Limited
BioNTech AG
Bioo Therapeutics
BiOrion Technologies B.V.
Biotecnol, Inc.
Biotest AG
Biscayne Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Cancer Therapeutics CRC Pty Ltd
Cavion LLC
CEL-SCI Corporation
Celgene Corporation
Cellceutix Corporation
Celltrion, Inc.
Celsion Corporation
Cerulean Pharma, Inc.
China Grand Wuhan General Pharmaceutical Research Institute
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp.
Chugai Pharmaceutical Co., Ltd.
CIMAB S.A.
Clovis Oncology, Inc.
Cold Genesys, Inc.
Compugen Ltd.
Coronado Biosciences, Inc.
Covagen AG
Critical Outcome Technologies Inc.
Curadev Pharma Private Limited
Curaxys, S.L.
CureFAKtor Pharmaceuticals. LLC
Curis, Inc.
Cyclacel Pharmaceuticals, Inc.
CytomX Therapeutics, Inc.
CZ BioMed Corp
Daiichi Sankyo Company, Limited
Debiopharm International S.A.
Deciphera Pharmaceuticals, LLC
Dendreon Corporation
DexTech Medical AB
Digna Biotech, S.L.
DiNonA Inc.
Dong-A Socio Group
Dongkook Pharmaceutical Co., Ltd.
DormaTarg, Inc.
Egenix, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EndoCeutics, Inc.
Endocyte, Inc.
EntreChem, S.L.
Epigen Biosciences, Inc.
Epirus Biopharmaceuticals, Inc.
Erytech Pharma SA
Esperance Pharmaceuticals, Inc.
Etubics Corporation
Evgen Limited
Exelixis, Inc.
F-Star
F-star Alpha Ltd.
F. Hoffmann-La Roche Ltd.
FibroStatin SL
FirstString Research, Inc.
G1 Therapeutics, Inc.
Galapagos NV
Galectin Therapeutics, Inc.
Galena Biopharma, Inc.
Galileo Research s.r.l.
Ganymed Pharmaceuticals AG
GeneFrontier Corporation
Genelux Corporation
Genentech, Inc.
Genor BioPharma Co., Ltd.
GenSpera, Inc.
GlaxoSmithKline plc
Glycotope GmbH
Green Cross Corporation
GTx, Inc.
GW Pharmaceuticals plc
Hanmi Pharmaceuticals, Co. Ltd.
Hanwha Chemical Co., Ltd.
Harbor Therapeutics, Inc.
Heat Biologics, Inc.
Helix BioPharma Corp.
Hemispherx Biopharma, Inc.
Histogen, Inc.
Huabo Biopharm Co., Ltd.
Hutchison MediPharma Limited
Ignyta, Inc.
Ildong Pharmaceutical Co., Ltd.
ImmunoFrontier, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Immunophotonics Inc
Immunovaccine, Inc.
IMPACT Therapeutics, Inc.
Incuron, LLC
Incyte Corporation
Inovio Pharmaceuticals, Inc.
Intica Biomedical, Inc.
Invictus Oncology Pvt. Ltd.
Io Therapeutics, Inc.
Ipsen S.A.
Jasco Pharmaceuticals, LLC.
Jeil Pharmaceutical Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Johnson & Johnson
JW Pharmaceutical Corporation
Kadmon Corporation, LLC
Kalos Therapeutics, Inc.
Kancera AB
Keystone Nano, Inc.
Kinex Pharmaceuticals, LLC
Kyowa Hakko Kirin Co., Ltd.
Laboratoires Pierre Fabre SA
Laboratorio Elea S.A.C.I.F. and A
Laboratorios Farmaceuticos Rovi, S.A.
Les Laboratoires Servier SAS
Lipopharma Therapeutics SL
LondonPharma Ltd
Lytix Biopharma AS
Mabion SA
MacroGenics, Inc.
MandalMed, Inc.
Meabco A/S
Mebiopharm Co., Ltd.
MediaPharma s.r.l.
Medicon Pharmaceuticals, Inc
MedImmune, LLC
Medivation, Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Merrion Pharmaceuticals Plc
Millennium Pharmaceuticals, Inc.
Mission Therapeutics Ltd
Molecular Partners AG
Molecular Templates Inc.
Momenta Pharmaceuticals, Inc.
MultiCell Technologies, Inc.
Multimmune GmbH
Nanobiotix
NanoCarrier Co., Ltd.
Natco Pharma Limited
Nemucore Medical Innovations, Inc.
Netherlands Translational Research Center B.V.
Nexgenix Pharmaceuticals, LLC
Nexigen GmbH
Novartis AG
NuCana BioMed Limited
Oasmia Pharmaceutical AB
Omnitura Therapeutics Inc.
Oncbiomune, L.L.C.
Oncobiologics, Inc.
OncoEthix SA
Oncogenex Pharmaceuticals, Inc.
Oncolix, Inc.
Oncology Research International Limited
Oncomatrix, S.L.
OncoMax
Onconova Therapeutics, Inc.
Oncothyreon Inc.
Oncovir, Inc.
OncoVista Innovative Therapies, Inc.
Ono Pharmaceutical Co., Ltd.
Orega Biotech SAS
OSE Pharma SA
Otsuka Holdings Co., Ltd.
Oxford BioTherapeutics Ltd
Pacific Northwest Biotechnology, LLC
Panacea Biotec Limited
Pantarhei Bioscience BV
Paras Biopharmaceuticals Finland Oy
Patrys Limited
Pfizer Inc.
Pharma Two B Ltd
Pharmacyclics, Inc.
Pharmicell Co., Ltd.
Pharminox Limited
Plantacor, Inc.
Plexxikon Inc.
Precision Biologics, Inc.
Priaxon AG
ProMetic Life Sciences Inc.
Provectus Biopharmaceuticals, Inc.
Puma Biotechnology, Inc.
Qu Biologics Inc.
Quantum Pharmaceuticals
Quintessence Biosciences, Inc.
Radius Health, Inc.
Recepta Biopharma S.A.
Recombio S.L
Regulon Inc.
Reliance Life Sciences Pvt. Ltd.
Repros Therapeutics Inc.
Rexahn Pharmaceuticals, Inc.
Richter Gedeon Nyrt.
Rigontec GmbH
Sanofi
Sareum Holdings plc
Scancell Holdings Plc
Seek
Selvita SA
Shanghai Henlius Biotech Co., Ltd.
Shenogen Pharma Group Ltd.
Shionogi & Co., Ltd.
Sihuan Pharmaceutical Holdings Group Ltd.
SillaJen Co. Ltd.
Sirnaomics, Inc.
SK Chemicals Co., Ltd.
Soricimed Biopharma Inc.
Spectrum Pharmaceuticals, Inc.
Sphaera Pharma Pvt. Ltd.
Sprint Bioscience AB
Supratek Pharma Inc.
Synta Pharmaceuticals Corp.
Synthon BV
Takara Bio Inc.
Takeda Pharmaceutical Company Limited
TapImmune Inc.
Terpenoid Therapeutics, Inc.
Tesaro, Inc.
Teva Pharmaceutical Industries Limited
Theraclone Sciences, Inc.
THERAVECTYS SA
TheRyte Ltd.
TRACON Pharmaceuticals, Inc.
TransTech Pharma, Inc.
TREAT U, S.A.
Trojantec ltd.
TVAX Biomedical, Inc.
Vaccinex, Inc.
ValiRx Plc
Vasgen Limited
Vaxeal Holding SA
Vaxon Biotech
Verastem, Inc.
VG Life Sciences, Inc.
Viralytics Ltd.
Virax Holdings Limited
ViroMed Co., Ltd.
Visionary Pharmaceuticals, Inc.
Viventia Biotechnologies Inc.
Welichem Biotech Inc.
Zensun (Shanghai) Sci & Tech Co., Ltd.
Zymeworks Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[乳がん(Breast Cancer):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆